Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction-Reference-Cited by-同舟云学术

Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction

Published:2017-10 Issue:10 Volume:10 Page:
ISSN:1941-7713
Container-title:Circulation: Cardiovascular Quality and Outcomes
language:en
Short-container-title:Circ Cardiovasc Qual Outcomes

Author:

Booth John N.¹,Colantonio Lisandro D.¹,Chen Ligong¹,Rosenson Robert S.¹,Monda Keri L.¹,Safford Monika M.¹,Kilgore Meredith L.¹,Brown Todd M.¹,Taylor Benjamin¹,Dent Ricardo¹,Muntner Paul¹,Levitan Emily B.¹

Affiliation:

1. From the Department of Epidemiology (J.N.B., L.D.C., L.C., P.M., E.B.L.), Department of Health Care Organization and Policy (M.L.K.), and Department of Medicine (T.M.B), University of Alabama at Birmingham, AL; Department of Medicine, Mount Sinai Icahn School of Medicine, New York, NY (R.S.R.); Center for Observational Research (K.L.M., B.T.) and Global Development (R.D.), Amgen Inc., Thousand Oaks, CA; and Department of Medicine, Weill Cornell Medicine, New York, NY (M.M.S.)

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference28 articles.

1. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

2. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

3. Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT] Study)††Conflicts of interest: Dr. LaRosa has served as a consultant to Pfizer, Inc., New York, New York; Merck Whitehouse Station, New Jersey; Bristol-Myers Squibb, New York, New York; and AstraZeneca, Wilmington, Delaware; and has received lecture fees from Pfizer. Dr. Grundy has consulted with Abbott, Chicago, Illinois; GlaxoSmithKline, Durham, North Carolina, Pfizer, AstraZeneca, and Sanofi-Aventis, Bridgewater, New Jersey; received lecture fees from Merck Schering Plough, Kenilworth, New Jersey; Kos, Edison, New Jersey, Pfizer, GlaxoSmithKline, Lilly, and Bristol-Myers Squibb; and received research support from Abbott and GlaxoSmithKline. Dr. Kastelein has received consulting fees, lecture fees, and grant support from Pfizer, Merck Schering Plough, Bristol-Myers Squibb, and Sankyo, Munich, Germany; Dr. Kostis has served as a consultant to Pfizer, Schering Plough, Berlex, Montville, New Jersey; Taisho, Tokyo, Japan; Forest Laboratories, New York, New York; and Sankyo; received lecture fees from Pfizer, Merck, Bristol-Myers Squibb, AstraZeneca, Sanofi Aventis, and Otsuka, Rockville, Maryland; and received grant support from Pfizer and Schering Plough. Dr. Greten has received consulting and lecturing fees from Pfizer, Merck, Schering Plough, and Kowa Company, Nagoya, Japan.

4. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.;National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III);Circulation,2002

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statin Discontinuation: Global Challenge in Secondary Prevention;The American Journal of Cardiology;2024-02

2. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial;Circulation;2024-01-30

3. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort;Current Medical Research and Opinion;2023-11-23

4. Potentially inappropriate medications in older adults with Parkinson disease before and after hospitalization for injury;Parkinsonism & Related Disorders;2023-09

5. Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study;American Journal of Preventive Cardiology;2023-06